<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11860574</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.730</article-id><article-id pub-id-type="other">EPP0626</article-id><article-id pub-id-type="pii">S0924933824007302</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Anxiety disorders and intravenous drug use in chemsex context</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Curto Ramos</surname><given-names>J.</given-names></name><xref rid="aff1738" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff1739" ref-type="aff">
<sup>2</sup>
</xref><xref rid="cor0591" ref-type="corresp">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rodr&#x000ed;guez Laguna</surname><given-names>A.</given-names></name><xref rid="aff1739" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Barrio</surname><given-names>P.</given-names></name><xref rid="aff1739" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Ibarguchi</surname><given-names>L.</given-names></name><xref rid="aff1739" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Garc&#x000ed;a</surname><given-names>A.</given-names></name><xref rid="aff1739" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Azqueta</surname><given-names>I.</given-names></name><xref rid="aff1739" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dolengevich Segal</surname><given-names>H.</given-names></name><xref rid="aff1740" ref-type="aff">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="aff1738"><sup>1</sup>Department of Psychiatry, Clinical Psychology and Mental Health, <institution>La Paz University Hospital</institution></aff><aff id="aff1739">
<sup>2</sup>
<institution>Apoyo Positivo</institution>
</aff><aff id="aff1740"><sup>3</sup>Dual Disorders Program. Department of Psychiatry, <institution>Henares University Hospital</institution>, <city>Madrid</city>, <country>Spain</country></aff><author-notes><corresp id="cor0591"><label>*</label>Corresponding author.</corresp></author-notes><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="705">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S354</fpage><lpage>S354</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824007302a.pdf"/><abstract><sec id="sec3552"><title>Introduction</title><p>Several studies have called atention to the mental health disorders associated with chemsex -the intentional use of drugs before or during sexual intercourse GBMSM (gay, bisexual and men who have sex with men) population-. Sexualized intravenous drug use is also known as slam or slamsex. There are few studies that analyze the mental health differences between intravenous drug users&#x000a0;compared to non-intravenous&#x000a0;drug users in chemsex context.</p></sec><sec id="sec3553"><title>Objectives</title><p>We aim to describe the mental health outcomes including current and past anxiety disorders diagnosis in a sample of users with sexualized drug use (chemsex) attended by the non-governmental organization Apoyo Positivo in the program &#x0201c;Sex, Drugs and You&#x0201d; and to compare the differences of current and previous diagnosis of anxiety disorders between intravenous drug users compared to non-intravenous drug users.</p></sec><sec id="sec3554"><title>Methods</title><p>A cross-sectional descriptive analysis of a sample of users attended by the non-governmental organization Apoyo Positivo in the program &#x0201c;Sex, Drugs and You&#x0201d; between 2016-2019 was performed.</p></sec><sec id="sec3555"><title>Results</title><p>We included 217 participants. Current or past diagnosis of anxiety disorders was found in 142 participants. Anxiety disorders were significantly higher in the intravenous drug use group compared to the non-intravenous drug use group (p&#x0003c;0.05).</p></sec><sec id="sec3556"><title>Conclusions</title><p>Previous studies have reported that MSM who practiced chemsex were more likely to experience from anxiety. In our study, anxiety disorders where higher in participantes who engaged in intravenous drug use. A multidisciplinary team&#x000a0;is necessary to address chemsex and provide care and treatment for mental health problems such as anxiety, depression, suicidal behaviour or drug-induced psychosis.</p></sec><sec id="sec3557"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>